Related Experiment Video

Updated: Jul 16, 2026

In vitro Mesothelial Clearance Assay that Models the Early Steps of Ovarian Cancer Metastasis
08:54

In vitro Mesothelial Clearance Assay that Models the Early Steps of Ovarian Cancer Metastasis

Published on: February 17, 2012

15.0K

Same-day discharge in advanced ovarian cancer as a milestone of surgical evolution and patient selection

Nuria Agusti1, J Alejandro Rauh-Hain1

  • 1Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Gynecologic Oncology
|March 25, 2026
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

8.1K
Author Spotlight: Advanced Ex Vivo Model for Investigating Cancer-Adipose Microenvironment Interaction
05:42

Author Spotlight: Advanced Ex Vivo Model for Investigating Cancer-Adipose Microenvironment Interaction

Published on: January 26, 2024

3.3K

Related Experiment Videos

Last Updated: Jul 16, 2026

In vitro Mesothelial Clearance Assay that Models the Early Steps of Ovarian Cancer Metastasis
08:54

In vitro Mesothelial Clearance Assay that Models the Early Steps of Ovarian Cancer Metastasis

Published on: February 17, 2012

15.0K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

8.1K
Author Spotlight: Advanced Ex Vivo Model for Investigating Cancer-Adipose Microenvironment Interaction
05:42

Author Spotlight: Advanced Ex Vivo Model for Investigating Cancer-Adipose Microenvironment Interaction

Published on: January 26, 2024

3.3K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Articles linked to this work by shared authors, journal, and citation graph.

Facilitated Cascade Genetic Testing for Relatives of Individuals With BRCA1/2 Pathogenic Variants: A Randomized Controlled Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Survival associated with recommended risk-reducing interventions for individuals with pathogenic variants in BRCA1/2.

Gynecologic oncology·2026

Planning and feasibility of phase III surgical trials in gynecologic oncology.

Gynecologic oncology·2026

Treatment strategies for oligometastatic and oligorecurrent epithelial ovarian cancer: a narrative review.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2026

The science and conduct of surgical trials in gynecologic oncology: A practical framework.

Gynecologic oncology·2026

A Multilevel Intervention to Identify Individuals for Genetic Testing and Treatment: The IGNITE-TX Pilot Randomized Clinical Trial.

JAMA network open·2026

Real-world outcomes of first-line pembrolizumab monotherapy among dMMR/MSI-H advanced or recurrent endometrial cancer patients in the United States.

Gynecologic oncology·2026

Platinum resistant ovarian cancer - No longer a graveyard for drug development.

Gynecologic oncology·2026

Molecular biomarkers in uterine sarcomas: a review of reviews with genomic data integration.

Gynecologic oncology·2026

Farletuzumab ecteribulin, a folate receptor alpha (FRα) antibody-drug conjugate, in select advanced cancers: An open-label, multicenter, phase 1/2 dose-finding study.

Gynecologic oncology·2026

Prevalence of pathogenic germline variants and indications for testing in a diverse community-based endometrial cancer cohort.

Gynecologic oncology·2026

Real-world clinical efficacy of pembrolizumab in combination with bevacizumab and oral metronomic cyclophosphamide in heavily pretreated platinum-resistant ovarian cancer.

Gynecologic oncology·2026

Peri-interventional neutrophil extracellular traps and immune surveillance in hepatocellular carcinoma: mechanisms, biomarkers, and recurrence after liver resection or thermal ablation.

Frontiers in oncology·2026

Enhancing intravesical bladder cancer therapy: from mucoadhesive to targeted drug delivery strategies.

Frontiers in medicine·2026

Gefitinib-based therapy in refractory hepatocellular carcinoma with EGFR overexpression: a spatial profiling-guided case report.

Frontiers in immunology·2026

Lysosome-Bursting Calcium Carbonate Nanoparticles Amplify Immunogenic Cell Death via Synergistic Phototherapy and Calcium Overload for Immune Checkpoint Blockade.

Research (Washington, D.C.)·2026

Bio-based nanophotothermal systems as smart drug delivery platforms for multimodal synergistic cancer therapy-a review.

Frontiers in medical technology·2026

Stable disease after multimodal treatment of SMARCA4-deficient undifferentiated tumor concurrently involving the stomach and mediastinum: a case report.

Frontiers in oncology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us